Clinical Trial Search

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B — 0…

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001

Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg

Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL

Primary: Hepatic Glucose Release — 1.85; 1.46; 1.54; 1.88 mg/kg/min

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year

Primary: Body Composition — 39; 39; 37; 39 percentage

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants

Primary: Pre- and Post-Intervention Triglyceride Levels — 231; 209; 201; 140 mg/dL

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 15; 10; 13 participants

Primary: LDL Level Change From Baseline — -63.4; -54.6 mg/dl — p=0.391

Primary: Change in Flow-mediated Dilation From Baseline to 4 Hours — 0.16; -3.2; -0.9; -2.4 percent change in diameter

Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml

Primary: Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects. — 13 mmHg

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL

Primary: Change in BMI Standard Deviation Score — -0.12; -0.06 Standard Deviation Score — p=0.007

Primary: TG Change (mg/dL ) — -9.2; 14.6; -4.2; -1.3 percentage of change

Primary: Percentage Change in Serum Triglyceride Levels From Baseline to Week 12 of Study Treatment — -39.1; -14.6 Percent change (%) — p=<0.01

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months — -0.37; -1.78; -0.29; 0.00 mg/dL

Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001

Primary: Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA) — 80.0; 81.3; 80.5 Percentage of total HUFA

Primary: Difference Between Treatments in Liquid Meal Tolerance Test (LMTT) Matsuda Insulin Sensitivity Index (MISI). — 3.2; 3.3 Index value — p=0.959